Just like ZEPBOUND (tirzepatide), its a dual GLP-1/GIP receptor agonist and a peptide-based biologic that requires a subcutaneous injection, but instead of once-a-week dosing, its once-monthly dosing
Any medical treatment, including GLP-1 therapy, should be undertaken only under direct medical supervision
however, their use is limited due to the development of intolerable anticholinergic adverse events, including confusion, drowsiness, memory impairment, dry mouth, constipation, and visual changes
Weight Management Promotes fat metabolism and may assist in healthy weight loss when combined with diet and exercise
For people with type 2 diabetes , the first study to report data will have a 40-week endpoint
Doomsday reports are constantly being published and it often seems we have little power in our day-to-day lives to make a real impact